Zenovel Expands Its Global Vision, Bringing Integrated Pharmaceutical Solutions To The World Stage At Cphi Milan 2026
Zenovel is set to showcase its integrated pharmaceutical consulting, regulatory, quality, & clinical research solutions at CPhI Milan 2026, reinforcing its growing global presence across 45+ countries
The pharmaceutical industry is undergoing a profound transformation. As regulatory expectations continue to evolve, drug development timelines become increasingly compressed, and quality standards grow more stringent, pharmaceutical and biotechnology companies are looking beyond conventional service providers. Today, organizations need strategic partners who can seamlessly integrate quality, regulatory expertise, and operational excellence to accelerate innovation while ensuring global compliance.
Against this backdrop, Zenovel, a rapidly growing pharmaceutical consulting and service organization, is strengthening its position as a trusted global partner with an integrated portfolio of quality assurance, regulatory affairs, clinical research, and pharmaceutical consulting services. As another milestone in its growth journey, the company will be exhibiting at CPhI Milan 2026, one of the world's premier pharmaceutical networking and sourcing events, bringing together innovators, manufacturers, regulators, and solution providers from across the global life sciences industry.
Founded in 2020 with the vision of delivering "Quality Beyond Compliance," Zenovel has rapidly established itself as a reliable partner for pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide. In just a few years, the company has built an impressive global footprint, supporting more than 250 clients across over 45 countries, backed by a multidisciplinary team with over 20 years of industry expertise. This combination of scientific knowledge, regulatory excellence, and operational agility has enabled Zenovel to support organizations ranging from emerging biotech companies to multinational pharmaceutical manufacturers.
What distinguishes Zenovel is its integrated approach to pharmaceutical quality and compliance. Rather than viewing regulatory requirements as standalone activities, the company combines scientific expertise, regulatory intelligence, quality systems, and operational execution into comprehensive solutions that support organizations throughout the product lifecycle. By helping clients strengthen quality management systems, improve inspection readiness, and simplify regulatory pathways, Zenovel enables organizations to focus on their primary objective of bringing safe and effective therapies to patients worldwide.
Today, Zenovel's capabilities span the entire pharmaceutical value chain. Its clinical research division provides GCP audits, sponsor oversight, risk-based monitoring, project management, PK statistical review, contract staffing, and quality assurance for clinical studies. In manufacturing and quality, the company delivers GMP audits, supplier qualification, Greenfield project support, plant setup and upgradation consulting, QMS implementation, Computer System Validation (CSV), certification support, and inspection readiness programs. Complementing these services is a comprehensive Regulatory Affairs practice offering regulatory intelligence, gap analysis, dossier preparation and review, eCTD compilation, lifecycle management, biologics registration, due diligence, and post-submission support for global markets.
Under the leadership of Mr. Rakesh Sutariya, MD & CEO, Zenovel continues to expand its global presence while remaining committed to scientific excellence and ethical business practices.
"At Zenovel, we believe in going beyond compliance. Our philosophy centres on innovation, collaboration, and ethical integrity. We don't just offer services. We deliver solutions that simplify regulatory complexities, allowing our clients to focus on innovation and ensuring safe and effective treatments reach patients worldwide. As we continue to expand globally, our commitment to quality and integrity remains at the heart of everything we do."
This philosophy has helped Zenovel earn industry recognition, including being named among the Top 10 Pharmaceutical Regulatory Consultants 2024 by India Pharma Outlook. The recognition reflects the company's consistent focus on quality, customer-centric delivery, and regulatory excellence, while reinforcing its reputation as a trusted partner for pharmaceutical organisations operating in increasingly regulated global markets.
As part of its continued international expansion, Zenovel will exhibit at CPhI Milan 2026, where the company will showcase its integrated expertise across GCP, GMP, Regulatory Affairs, CSV, Quality Management Systems, and Greenfield pharmaceutical projects. The event represents an important opportunity to engage with pharmaceutical manufacturers, biotechnology companies, CROs, CDMOs, sponsors, and regulatory professionals from around the world, while strengthening existing partnerships and exploring new collaborations.
For Zenovel, participation at CPhI Milan is not simply about exhibiting its services. It reflects the company's broader vision of contributing to the future of pharmaceutical quality by fostering global collaboration, sharing best practices, and helping organisations navigate increasingly complex regulatory environments through practical, science-driven solutions.
Looking ahead, Zenovel continues to invest in expanding its scientific capabilities, strengthening international partnerships, and embracing digital technologies that enhance quality management and regulatory efficiency. With a growing global client base spanning more than 45 countries, Zenovel is well positioned to support the evolving needs of the pharmaceutical and life sciences industry through flexible, science-driven consulting and quality solutions.
As pharmaceutical innovation accelerates worldwide, Zenovel remains committed to its founding philosophy of delivering "Quality Beyond Compliance." By combining deep scientific expertise, regulatory confidence, operational excellence, and a client-centric approach, the company continues to help organisations navigate complexity with confidence while contributing to the development of safer, more effective healthcare solutions for patients across the globe.
Disclaimer: This is a sponsored article. ABP Network Pvt. Ltd. and/or ABP Live does not in any manner whatsoever endorse/subscribe to the contents of this article and/or views expressed herein. Reader discretion is advised.
